Amanda Scartezini Gozdziejewski
Research Subjects
Research Interests
Amanda Scartezini Gozdziejewski has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- André Luiz Grion
Pelé Pequeno Príncipe Research Institute, 1532 Silva Jardim, AV., Curitiba 80250-200, PR, Brazil
1 shared publication - Bonald Cavalcante Figueiredo
Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba 80250-060, PR, Brazil
1 shared publication - Clarice Wichinescki Zotti
Pelé Pequeno Príncipe Research Institute, 1532 Silva Jardim, AV., Curitiba 80250-200, PR, Brazil
1 shared publication - Emanuelle Nunes de Souza
Pelé Pequeno Príncipe Research Institute, 1532 Silva Jardim, AV., Curitiba 80250-200, PR, Brazil
1 shared publication - Gislaine Custódio
Centro de Genética Molecular e Pesquisa do Câncer em Crianças-CEGEMPAC, Universidade Federal do Paraná, Avenida Agostinho Leão Junior, 400, Alto da Glória, Curitiba 80030-110, PR, Brazil
1 shared publication - Guilherme Augusto Parise
Pelé Pequeno Príncipe Research Institute, 1532 Silva Jardim, AV., Curitiba 80250-200, PR, Brazil
1 shared publication
Latest Publications
- Open Access
Psychological Impact of TP53-Variant-Carrier Newborns and Counselling on Mothers: A Pediatric Surveillance Cohort
Counselling and genetic testing (CGT) after neonatal screening may increase depression and anxiety (DA) levels during cancer surveillance. This study assessed the DA scores in mothers of newborns from Paraná state, Southern Brazil, carrying the TP53 p.R337H variant. To understand and adjust DA conditions during term of pregnancy, we initially detected sociodemographic covariates [marital status (MS), number of children (NC), and/or education level (EL): MS-NC-EL] on an independent group of pregnant women (not subjected to genetic testing). The Hospital Anxiety and Depression Scale (HADS) was used to assess risk factors in pregnant (cross-sectional analysis) and unrelated mothers (at 2-month intervals, longitudinal study) of TP53 p.R337H-tested newborns (three sessions of HADS analysis) using Wilcoxon (Mann–Whitney) and Kruskal–Wallis nonparametric tests. Lower anxiety levels were observed in mothers of noncarriers (without MS-NC-EL = 6.91 ± 1.19; with MS-NC-EL = 6.82 ± 0.93) than in mothers of p.R337H carriers in the first session (without MS-NC-EL = 6.82 = 8.49 ± 0.6025, with MS-NC-EL = 6.82 = 9.21 ± 0.66). The anxiety levels significantly decreased 4 months after CGT (third session) in mothers of p.R337H carriers. We did not find a significant change in depression scores. Mothers with mental health instability requiring medications need periodical psychological support during and after CGT.
Open AccessPsychological Impact of TP53-Variant-Carrier Newborns and Counselling on Mothers: A Pediatric Surveillance Cohort
Counselling and genetic testing (CGT) after neonatal screening may increase depression and anxiety (DA) levels during cancer surveillance. This study assessed the DA scores in mothers of newborns from Paraná state, Southern Brazil, carrying the TP53 p.R337H variant. To understand and adjust DA conditions during term of pregnancy, we initially detected sociodemographic covariates [marital status (MS), number of children (NC), and/or education level (EL): MS-NC-EL] on an independent group of pregnant women (not subjected to genetic testing). The Hospital Anxiety and Depression Scale (HADS) was used to assess risk factors in pregnant (cross-sectional analysis) and unrelated mothers (at 2-month intervals, longitudinal study) of TP53 p.R337H-tested newborns (three sessions of HADS analysis) using Wilcoxon (Mann–Whitney) and Kruskal–Wallis nonparametric tests. Lower anxiety levels were observed in mothers of noncarriers (without MS-NC-EL = 6.91 ± 1.19; with MS-NC-EL = 6.82 ± 0.93) than in mothers of p.R337H carriers in the first session (without MS-NC-EL = 6.82 = 8.49 ± 0.6025, with MS-NC-EL = 6.82 = 9.21 ± 0.66). The anxiety levels significantly decreased 4 months after CGT (third session) in mothers of p.R337H carriers. We did not find a significant change in depression scores. Mothers with mental health instability requiring medications need periodical psychological support during and after CGT.